Pyramid Biosciences Names Biren Amin as Chief Financial and Strategy Officer

Rhea-AI Summary

Pyramid Biosciences has expanded its leadership team by appointing Biren Amin as Chief Financial and Strategy Officer. Amin, previously CFO at Immuneering Corporation (NASDAQ: IMRX), brings over two decades of experience in oncology and biotechnology. The company is focused on developing precision therapies for cancer, particularly with its lead program PBI-200, a TRK inhibitor for NTRK fusion-driven cancers. The CEO expressed confidence in Amin's expertise to guide corporate strategy and advance the product pipeline during a period of significant growth for the company.

Positive

• Appointment of Biren Amin as Chief Financial and Strategy Officer.
• Amin's experience includes a successful $120 million IPO at Immuneering.
• Company's focus on clinical-stage precision therapies, specifically PBI-200.

Negative

• None.

• Mr. Amin will oversee the advancement and expansion of the Company’s pipeline

• Mr. Amin joins Pyramid Biosciences from Immuneering Corporation where he served as Chief Financial Officer

• Pyramid Biosciences’ pipeline is focused on clinical-stage precision medicines, including its lead program PBI-200, a next-generation, highly CNS penetrant tropomyosin receptor kinase (TRK) inhibitor for patients with NTRK fusion-driven cancers

WALTHAM, Mass.--(BUSINESS WIRE)-- Pyramid Biosciences, Inc., a Boston-based, clinical-stage, biotechnology company focused on developing new and highly differentiated precision therapies for cancer, today announced the expansion of its senior leadership team. Biren Amin, M.S., M.B.A. has joined the company as its Chief Financial and Strategy Officer. Mr. Amin comes to Pyramid Biosciences from Immuneering Corporation (NASDAQ: IMRX), where he previously served as the company’s Chief Financial Officer (CFO).

“We are delighted Biren has joined our leadership team, particularly at this time of significant growth for the Company,” said Brian Lestini, M.D., Ph.D., CEO of Pyramid Biosciences. “His achievements over two decades in oncology and biotech, both in the capital markets and industry, are impeccable and second to none. As we strive to serve patients through advancing and expanding our pipeline, Biren’s strategic leadership and expertise will play a critical role in fulfilling our mission.”

“I look forward to working with the outstanding team at Pyramid Biosciences as we advance our best-in-class NTRK inhibitor, PBI-200, through clinical development and diversify our pipeline” said Mr. Amin. “My focus will be to ensure that our corporate strategy and business development activities align with our goal of bringing cutting-edge investigational therapies in oncology to the Company and to patients.”

Prior to joining Pyramid Biosciences, Mr. Amin served as CFO at Immuneering Corporation, a pre-clinical, US-based, biopharmaceutical company focused on oncology, where he successfully led a $120 million initial public offering. Previously, Mr. Amin spent nearly two decades on Wall Street where he built a strong track record covering small-mid cap biotechnology companies, focusing on oncology, CNS disorders, ophthalmology, and rare diseases. Mr. Amin spent a decade at Jefferies Financial Group as Managing Director in their Equity Research group. During this time, Mr. Amin was named Best Stock Picker in Biotechnology in 2013 by Financial Times. Prior to joining Jefferies, Mr. Amin was an equity research analyst covering biotechnology and pharmaceuticals at several firms including Prudential Equity Group. He began his career at Aventis Pharmaceuticals (currently part of Sanofi S.A.) where he served as the Senior Manager in their Scientific Competitive Intelligence group. Mr. Amin received his Bachelor of Science (B.S.) degree in Pharmacy from the University of the Sciences in Philadelphia, his Master of Science (M.S.) degree in Pharmacy from Long Island University, and his Master of Business Administration (M.B.A.) from the Stern School of Business at New York University. He currently sits on the Board of Trustees of Axiom REACH Foundation.

About Pyramid Biosciences:

Founded in 2015, Pyramid Biosciences is a clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer. Based in Boston, Massachusetts, Pyramid Biosciences is currently in clinical development of two highly selective tropomyosin receptor kinase (TRK) inhibitors. For more information, please visit: www.pyramidbio.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005480/en/

Pyramid Biosciences Media Inquiries:

McDougall Communications on behalf of Pyramid Biosciences

Elizabeth Harness, +1-585-435-7379

elizabeth@mcdougallpr.com

Pyramid Biosciences Investor Inquiries:

Jordan Leef, Pyramid Biosciences, COO, and Co-Founder

+1-781-530-4461, info@pyramidbio.com

Source: Pyramid Biosciences, Inc.

FAQ

What recent leadership change occurred at Pyramid Biosciences?

Pyramid Biosciences appointed Biren Amin as Chief Financial and Strategy Officer.

What is the background of Biren Amin?

Biren Amin previously served as CFO at Immuneering Corporation and has extensive experience in oncology and biotech.

What is PBI-200?

PBI-200 is a next-generation TRK inhibitor being developed for NTRK fusion-driven cancers.

How does the appointment of Biren Amin affect Pyramid Biosciences?

Amin's strategic leadership is expected to enhance the company's growth and pipeline development.

What is the focus of Pyramid Biosciences?

Pyramid Biosciences specializes in developing differentiated precision therapies for cancer.